97.00Open97.00Pre Close0 Volume0 Open Interest390.00Strike Price0.00Turnover95.20%IV-16.34%PremiumDec 20, 2024Expiry Date138.16Intrinsic Value100Multiplier17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9899Delta0.0013Gamma1.82Leverage Ratio-0.0238Theta-0.0336Rho-1.80Eff Leverage0.0133Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet